Development of Small Airway Disease Questionnaire (SADQ)
This study has been completed.
Chiesi Farmaceutici S.p.A.
Information provided by (Responsible Party):
E. van der Wiel, University Medical Centre Groningen
First received: May 12, 2011
Last updated: June 27, 2013
Last verified: June 2013
The aim of this study is to develop a patient reported outcome tool specific to small airways disease, which assesses symptoms and signs of small airways disease and may help in addition to FEF50% to discriminate between asthmatic patients with and without small airways disease.
||Time Perspective: Prospective
||The Development of a Questionnaire to Assess Symptoms of Small Airways Disease in Patients With Asthma
Primary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2012 (Final data collection date for primary outcome measure)
Asthma with small airway disease
Asthma without small airway disease
Inflammation of the small airways contributes to the severity of the disease and affects the quality of life of patients with asthma. However, the exact role and relevance of small airways disease in asthma is still unclear. This is partly due to the difficulty of measuring small airways pathology with a sensitive and specific parameter. The most commonly used variable as an indicator of small airway obstruction is the FEF50%. Currently, it is not known which clinical symptoms are associated with small airways disease and how a patient will perceive small airway abnormalities. This knowledge is important to assess small airways disease in patients with asthma and adjust therapy to improve quality of life.The primary purpose of this study is to develop a questionnaire for patients with asthma with and without small airways disease for general and specialist practice.
|Ages Eligible for Study:
||18 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
The study population will contain a total of 60 adult patients with asthma, 30 patients with small airways disease and 30 patients without small airways disease.
- A doctor diagnosis of asthma
- Age: ≥ 18 and ≤ 75 years
- An FEF50% value that is included in either the lowest or the highest 25th percentile. (Percentiles based on the total asthma patient group present from Asthma/COPD service)
- Recent exacerbation of asthma (<2 months) or upper respiration tract infection (<2 weeks)
- Severe airway obstruction at baseline, FEV1pred< 50% or < 1.2L
- Diagnosis of COPD or another pulmonary disease
- Pregnancy or lactating women. (i.e. women of childbearing potential who do not use adequate anticonception as judged by the investigator).
- Restriction, defined as FVC < 80%pred with FEV1/FVC >0.7
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01360294
|University Medical Center Groningen
|Groningen, Netherlands, 9700RB |
University Medical Centre Groningen
Chiesi Farmaceutici S.p.A.
No publications provided
||E. van der Wiel, MD, University Medical Centre Groningen
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 12, 2011
||June 27, 2013
||Netherlands: Independent Ethics Committee
Keywords provided by University Medical Centre Groningen:
Small airways disease
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 20, 2014
Pulmonary Disease, Chronic Obstructive
Immune System Diseases
Lung Diseases, Obstructive
Respiratory Tract Diseases